One of the cannabis industry’s most significant takeover battles has escalated into an increasingly public fight over valuation, debt, international growth and the future structure of the global marijuana market. Curaleaf Holdings is attempting to acquire Canadian medical cannabis leader Aurora Cannabis through a hostile takeover bid, while Aurora’s board continues urging shareholders to reject the proposal and wait for potentially better strategic alternatives. Curaleaf increased its offer in October after Aurora rejected its original bid, but the higher price has done little to reduce tensions between the companies.
The latest round came after Aurora unanimously rejected Curaleaf’s revised offer of approximately US$5 per share. Curaleaf responded on October 19 by accusing Aurora’s board of excluding it from due diligence while simultaneously allowing unidentified potential buyers or strategic partners to examine confidential company information. Aurora maintains that the revised proposal still undervalues its global medical cannabis operations and leaves its shareholders carrying too much risk through Curaleaf stock. With the hostile offer currently scheduled to expire December 4, 2026, Aurora shareholders are effectively being asked to choose between accepting a premium today and betting that Aurora’s independent strategy—or another buyer—can ultimately produce greater value.
Curaleaf First Approached Aurora Privately
The dispute began months before the hostile bid became public. Curaleaf says it approached Aurora privately in June 2026 about a possible acquisition and followed with another proposal in July. Aurora acknowledged receiving letters dated June 23 and July 7 but disputed Curaleaf’s suggestion that management simply refused to engage. The companies communicated during the summer, but negotiations failed to develop into a friendly transaction.
Curaleaf eventually took the proposed acquisition directly to Aurora shareholders. On August 18, the company formally launched an unsolicited takeover offer valued at an implied US$4 per Aurora share. The original package consisted of US$0.75 in cash plus 0.3463 Curaleaf subordinate voting shares for each Aurora share, subject to a maximum value of US$5 per share. Curaleaf described the offer as representing a substantial premium to Aurora’s stock price before news of the proposed acquisition became public.
Aurora responded by forming a special committee of independent directors and advising shareholders not to tender their stock. After reviewing the proposal with financial and legal advisers, the board concluded that the initial bid significantly undervalued the company. That rejection transformed what Curaleaf had originally hoped could become a negotiated combination into a formal hostile takeover contest.
Curaleaf Raised the Offer to About $5 Per Share
Curaleaf increased the pressure on October 5 by improving the economics of its proposal. Under the revised bid, Aurora shareholders would receive US$1 in cash plus 0.4013 Curaleaf shares for every Aurora share. Based on Curaleaf’s trading price when the enhanced proposal was announced, the package carried an implied value of approximately US$5 per Aurora share. Curaleaf also increased the maximum possible value under the offer from US$5 to US$6 per share.
Curaleaf argues the enhanced proposal represents an 86 percent premium to Aurora’s unaffected 30-day volume-weighted average share price before the takeover approach became public. The company also calculates a much larger premium after subtracting Aurora’s substantial cash position from its valuation. From Curaleaf’s perspective, the new proposal provides shareholders with immediate value while allowing them to retain an ownership stake in the combined company rather than cashing out completely.
Most of the consideration, however, would still be paid in Curaleaf stock. Approximately 80 percent of the revised offer is equity rather than cash, meaning Aurora shareholders accepting the transaction would become Curaleaf shareholders and remain exposed to fluctuations in Curaleaf’s stock price. That structure has become one of Aurora’s central objections.
Aurora Says Even the Improved Offer Is Too Low
Aurora’s board formally rejected the revised proposal on October 14 after receiving another recommendation from its special committee and an updated financial opinion from adviser Fort Capital. The company argues that US$5 per share does not adequately compensate shareholders for Aurora’s balance sheet, international medical cannabis business, EU-GMP production infrastructure and long-term growth prospects.
Aurora ended June with approximately US$108 million in cash, restricted cash and short-term investments under the figures used in its takeover response, while reporting no funded debt. In its fiscal 2027 first-quarter results, the company reported C$149.1 million in cash, cash equivalents and short-term investments and emphasized that it remained debt-free. Aurora generated record global medical cannabis revenue of C$288.6 million during fiscal 2026, up 18 percent year over year, while adjusted EBITDA reached a record C$53.8 million.
Management argues those numbers demonstrate that Aurora is no longer the highly leveraged cannabis company that struggled through years of restructuring and asset impairments. Aurora has repositioned itself primarily around international medical marijuana and now holds significant operations in Canada, Germany, Poland, Australia and New Zealand. Its board believes Curaleaf is attempting to acquire those assets before their longer-term value is fully reflected in Aurora’s stock price.
Curaleaf Says Aurora Is Ignoring Its Recent Weakness
Curaleaf presents a very different interpretation of Aurora’s recent performance. The company argues Aurora’s board focuses heavily on its record fiscal 2026 results while giving too little attention to more recent quarterly deterioration. Curaleaf has pointed to declining revenue and adjusted EBITDA across recent quarters and Aurora’s own expectation that fiscal 2027 revenue and profitability will be lower than the previous year.
Aurora has attributed part of that weakness to changes in Canadian medical cannabis reimbursement and describes the pressure as an industry-related headwind rather than evidence that its international strategy is failing. Curaleaf argues that the decline is more meaningful and says Aurora shareholders face substantial uncertainty if they reject the takeover premium and remain invested in the standalone business.
The disagreement illustrates why the valuation question is so difficult. Aurora believes its strongest international markets are still developing and should be valued according to future medical cannabis growth. Curaleaf believes shareholders should give greater weight to current profitability, recent earnings trends and the possibility that Aurora may require additional time to translate international growth into stronger overall financial performance.
Curaleaf Wants Aurora’s International Medical Cannabis Platform
The strategic logic behind Curaleaf’s pursuit is relatively clear. Curaleaf is one of the largest cannabis operators in the United States, with cultivation, manufacturing and dispensary operations across numerous state markets. It has also been expanding internationally, particularly in Europe, but Aurora possesses a medical cannabis production and distribution platform that would be difficult and expensive to reproduce from scratch.
Aurora has EU-GMP-certified cultivation and manufacturing capabilities and strong positions in several international medical markets. Its acquisition of Safari Flower Company expanded that capacity further. Curaleaf estimates Aurora can provide access to more than 50 tonnes of annual EU-GMP cultivation and manufacturing capacity, complementing Curaleaf’s existing international facilities.
Curaleaf says the combined operation would span 17 countries and generate more than US$1.5 billion in trailing 12-month revenue and nearly US$350 million in adjusted EBITDA. The company also projects at least US$40 million in annual cost savings from overlapping corporate expenses, procurement, supply chains and international infrastructure. A combined Curaleaf-Aurora organization would have a pro forma market capitalization exceeding US$3 billion, potentially creating one of the world’s largest cannabis businesses.
Aurora Questions Curaleaf’s $40 Million Synergy Estimate
Aurora has challenged those projected savings, arguing that Curaleaf developed the US$40 million estimate without access to Aurora’s confidential internal information. Curaleaf’s updated financial disclosures indicate that its preliminary calculation relied partly on comparing selling, general and administrative costs relative to revenue and applying Curaleaf’s own cost structure to Aurora.
Aurora argues that approach is too simplistic because Curaleaf has not conducted a detailed review of its contracts, facilities, staffing, technology systems and international operations. It also says the estimate does not clearly account for integration costs or possible negative effects of combining the businesses. Aurora further notes that its shareholders would own only about 9 percent of the combined Curaleaf organization under the revised exchange ratio, meaning most of any future cost savings would economically benefit existing Curaleaf investors.
Curaleaf counters that Aurora itself created the problem by denying access to confidential financial information. The bidder says it cannot be expected to prepare a detailed integration plan while Aurora permits other potential transaction partners into its data room but excludes Curaleaf. That disagreement has now become one of the sharpest points in the takeover dispute.
Curaleaf Accuses Aurora of Blocking the Highest Public Bidder
On October 19, Curaleaf escalated its criticism by directly challenging Aurora’s decision to reject the enhanced proposal. Curaleaf CEO Boris Jordan accused Aurora’s board of keeping Curaleaf outside the due-diligence process while granting confidential access to unnamed third parties. Curaleaf argues that if Aurora genuinely wants to maximize shareholder value, the board should allow the only publicly disclosed bidder with a binding offer to examine the company’s internal information.
Aurora has confirmed that its special committee and advisers have contacted multiple parties while exploring alternatives to Curaleaf’s bid. The company has entered confidentiality and standstill agreements with several of them, allowing those groups to examine confidential financial and operational information. Aurora has not identified those parties or said whether any has made a competing proposal.
That process could become critical. Aurora’s board is effectively telling shareholders that accepting Curaleaf’s bid now could interfere with its effort to produce something better. Curaleaf responds that denying it equal access may actually prevent competitive bidding from maximizing Aurora’s sale price. Until another bidder emerges publicly, shareholders are left evaluating a real Curaleaf offer against strategic alternatives that remain largely theoretical.
Aurora’s Cash and Curaleaf’s Debt Have Become Major Battlegrounds
The financial structures of the two companies are another major source of disagreement. Aurora emphasizes that it has substantial cash and no funded debt. Curaleaf, by contrast, carries significant debt, leases and financing obligations. Aurora has highlighted approximately US$1.1 billion of those obligations as of June 30, including US$500 million of senior secured notes carrying an 11.5 percent interest rate.
Aurora argues that the approximately US$67 million total cash component of Curaleaf’s revised bid could effectively be funded by Aurora’s own cash once the companies combine. From Aurora’s perspective, Curaleaf would acquire a debt-free company with more cash on its balance sheet than Curaleaf needs to pay the cash portion of the takeover, while Aurora shareholders would surrender control of the remaining money.
Curaleaf dismisses that reasoning as a misunderstanding of acquisition economics. Cash on the target company’s balance sheet becomes part of the combined company after virtually any corporate acquisition, it argues. Curaleaf says the relevant question is whether Aurora shareholders receive fair total value for their shares, not whether the acquired company brings cash into the transaction. Curaleaf further argues that Aurora’s cash is already reflected in the valuation calculations underlying its premium.
The Stock Component Creates Additional Risk
Because most of the takeover consideration consists of Curaleaf shares, the actual value Aurora investors eventually receive could move substantially before the transaction closes. Curaleaf’s headline US$5 figure was calculated using its stock price around the time of the revised offer. If Curaleaf’s shares decline, the market value of the package could fall as well. The offer includes an upper cap but does not give Aurora shareholders a guaranteed floor protecting them from a major Curaleaf share-price decline.
Aurora says Curaleaf currently trades at relatively high valuation multiples compared with several U.S. cannabis peers, making an equity-heavy acquisition particularly advantageous for Curaleaf. In effect, Aurora argues Curaleaf is attempting to use what Aurora considers expensive stock to purchase Aurora assets at a discounted valuation.
Curaleaf rejects the assertion that its shares are inflated and notes that Aurora’s own financial adviser used Curaleaf’s trading price as a reference when evaluating the transaction. Curaleaf also says Aurora shareholders would benefit from owning part of a larger and more diversified cannabis business rather than remaining dependent on Aurora’s narrower medical-focused strategy.
U.S. Cannabis Reform Adds Another Layer to the Deal
The acquisition would also fundamentally change Aurora shareholders’ exposure to the United States. Aurora has deliberately concentrated on federally compliant medical cannabis markets outside the U.S. state-licensed marijuana system. Curaleaf, by contrast, operates one of America’s largest networks of state-legal cannabis businesses.
If federal U.S. cannabis policy becomes more favorable, Curaleaf could potentially receive a substantial valuation boost. Aurora shareholders accepting the takeover would participate in that upside through the Curaleaf shares they receive. Curaleaf has repeatedly presented this exposure as one of the transaction’s major benefits.
It also introduces regulatory and financial risk. Federal marijuana reform has moved far more slowly than investors once expected, and large U.S. cannabis operators continue facing tax, financing and capital-market restrictions that conventional industries do not. Aurora shareholders would therefore exchange a debt-free international medical cannabis company for a minority position inside a larger organization carrying greater leverage and much more direct exposure to American regulatory uncertainty.
December Deadline Puts the Decision in Shareholders’ Hands
Curaleaf’s revised takeover bid is scheduled to remain open until 11:59 p.m. Mountain Time on December 4, 2026, unless it is extended, withdrawn or modified. Aurora’s board is telling investors they do not need to act now and that shareholders who reject the offer simply need to avoid tendering their stock. The company continues evaluating other transactions as well as the possibility of remaining independent.
Curaleaf is pursuing the opposite strategy. It wants Aurora shareholders to focus on the immediate premium, Aurora’s recent operating challenges and the benefits of combining two complementary international cannabis platforms. The bidder is also increasing public pressure on Aurora’s directors to grant due-diligence access, raising the possibility that the hostile contest could still transition into negotiated discussions if Aurora decides Curaleaf’s proposal deserves further consideration.
The dispute has now become much larger than a disagreement over whether Aurora is worth US$4, US$5 or US$6 per share. It is a battle over two competing views of cannabis industry consolidation. Curaleaf believes scale, geographic diversification and combined infrastructure are becoming essential as global marijuana markets mature. Aurora believes its debt-free balance sheet and increasingly focused international medical strategy deserve a valuation that reflects long-term growth rather than short-term stock weakness.
One of Cannabis’ Most Important Takeover Battles Is Still Unresolved
The Curaleaf–Aurora contest could reshape the competitive structure of the international cannabis industry. A completed acquisition would combine one of the largest U.S. marijuana operators with one of the strongest established global medical cannabis companies, giving the enlarged Curaleaf operation significant positions across North America, Europe and other emerging markets.
But the transaction is far from settled. Aurora’s board has twice rejected Curaleaf’s approach, a search for other strategic options is underway, and Curaleaf is publicly questioning whether directors are giving shareholders a fair process. The enhanced offer has narrowed the valuation gap without ending the fundamental disagreement over what Aurora is worth.
Between now and the December deadline, the most important development may not be another public argument between the two companies but whether Aurora produces a credible competing transaction. If another bidder offers more, Aurora’s decision to resist Curaleaf could prove valuable. If no superior alternative emerges, shareholders may increasingly question whether rejecting a substantial takeover premium was worth the gamble. For now, the future of Aurora remains caught between an aggressive global consolidation strategy from Curaleaf and a board determined to prove that its company is worth more than the hostile bid on the table.
